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infant in comparison to no-screening strategy. Transferred to the entire birth cohort 
newborn screening is able to reduce total costs by 14 million € from the Austrian 
health care systems perspective each year. ConClusions: Funding the new-born 
screening saves money and is cost-effective for the Austrian health care system.
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objeCtives: When patients start their first injectable therapy, clinicians can choose 
between glucagon-like peptide-1 (GLP-1) agonists and basal insulins. This study 
investigates the cost-effectiveness of exenatide once weekly (Bydureon®), a GLP-1 
agonist, compared with insulin glargine in patients inadequately controlled with 
metformin (±sulfonylureas) based on long-term clinical evidence. Methods: The 
validated CARDIFF model was used to conduct the analyses. Clinical inputs were 
derived from a randomized clinical trial and a 3-year follow-up study of it comparing 
exenatide once weekly (ExQW) versus insulin glargine once daily. Based on these clini-
cal inputs and the United Kingdom Prospective Diabetes Study (UKPDS) equations, 
the model predicts disease progression and the number of micro- and macro-vascular 
complications, along with diabetes-specific and all-cause mortality. The perspective 
of the National Health Service in the UK was adopted over a lifetime horizon. Local 
unit costs and utility data were assigned to the appropriate model parameters to 
calculate total Quality-Adjusted-Life-Years (QALYs) and total costs. Deterministic 
and probabilistic sensitivity analyses (PSA) were conducted. Results: Long-term 
treatment with ExQW was well tolerated and associated with sustained glycaemic 
control and sustained weight loss over at least 3 years. Compared to glargine, ExQW 
in combination with metformin was associated with an incremental benefit of 0.123 
QALYs (95%CI: 0.057; 0.178) at an additional cost of £1,722 (95%CI: £1,396; £2,089), 
resulting in an incremental cost-effectiveness ratio of £13,967 per QALY gained. The 
PSA showed that at a willingness-to-pay threshold of £20,000 per QALY gained, ExQW 
treatment had an 83% probability to be cost-effective compared to the strategy includ-
ing glargine. Sensitivity analyses showed that results were robust to variation in 
model parameters that carry uncertainty. ConClusions: Exenatide once weekly in 
combination with metformin was shown to be a cost-effective treatment option as 
first injectable therapy in patients inadequately controlled with metformin within 
established UK cost-effectiveness thresholds.
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objeCtives: To update the cost-effectiveness of dapagliflozin (Forxiga®), a selective 
sodium-glucose co-transporter-2 (SGLT-2) inhibitor, compared with a sulphonylurea 
(SU) when added to metformin in patients inadequately controlled with metformin 
mono-therapy based on long-term clinical evidence. Methods: The published 
and validated CARDIFF diabetes model was used to conduct the analyses. Clinical 
inputs were derived from a 4-year follow-up study of a randomized clinical trial 
comparing dapagliflozin and glipizide in combination with metformin. Based on 
these clinical inputs and the United Kingdom Prospective Diabetes Study (UKPDS) 
equations, the model predicts disease progression and the number of micro- and 
macro-vascular complications, along with diabetes-specific and all-cause mor-
tality. The perspective of the National Health Service in England and Wales was 
adopted over a lifetime horizon. Local unit costs and utility data were assigned to 
the appropriate model parameters to calculate total Quality-Adjusted-Life-Years 
(QALYs) and total costs. Deterministic and probabilistic sensitivity analyses (PSA) 
were conducted. Results: Dapagliflozin showed greater durability of HbA1c reduc-
tion compared with SU and sustained weight loss over 4 years. Compared to SU 
added on top of metformin, dapagliflozin add-on to metformin was associated with 
an incremental benefit of 0.181 QALYs (95%CI: 0.088; 0.268) at an additional cost of 
£819 (95%CI: £415; £1,259), resulting in an ICER point estimate of £4,521 per QALY 
gained. The univariate analyses showed that no input parameter change inflated the 
ICER above £15,000 per QALY. The PSA showed that at a willingness-to-pay threshold 
of £20,000 per QALY gained, dapagliflozin treatment had an estimated 100% prob-
ability to be cost-effective compared to an SU treatment strategy. These findings 
were shown to be robust with all sensitivity analyses. ConClusions: Dapagliflozin 
in combination with metformin was shown to be a cost-effective treatment option 
for patients who are inadequately controlled with metformin mono-therapy within 
established UK cost-effectiveness thresholds.
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objeCtives: To evaluate the cost-effectiveness of canagliflozin in dual therapy as 
add-on to metformin compared to sitagliptin and in triple therapy as add-on to met-
formin (MET) and sulfonylurea (SU) compared to sitagliptin. Methods: The IMS 
CORE Diabetes Model was used to evaluate the cost-effectiveness of canagliflozin 
100 mg and 300 mg versus sitagliptin 100 mg using data from both clinical trials and 
network meta-analysis, combined with Portuguese-specific data when available. The 
perspective of the analysis is societal in accordance with Guidelines for Economic 
Drug Evaluation Studies from INFARMED. Results: The cost-effectiveness analyses 
indicate that canagliflozin (100 mg and 300 mg weighted average 65: 35) is cost-saving 
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objeCtives: To estimate the short-term cost-effectiveness of insulin detemir 
compared with Neutral Protamine Hagedorn (NPH) insulin when initiating insulin 
treatment in patients with Type 2 Diabetes Mellitus (T2DM) in Spain. Methods: A 
short-term (1 year) cost-effectiveness model was adapted to the Spanish public health 
care system. Based on a head-to-head randomized controlled trial (NCT00104182) 
that showed similar efficacy in glycemic control for both insulin types, weight gain 
(Δ = 0.9Kg) and the rate of non-severe hypoglycemia (between-arms RR= 0.52; IC95% 
0.44-0.61) of detemir vs. NPH were selected as clinical outcomes. Costs (Euros 2014) 
were estimated from the perspective of the Spanish national health system and 
derived from national public sources. Only insulin treatment and management costs 
associated with non-severe hypoglycemic episodes were included in the analysis. 
According to a published study, non-severe hypoglycemia (a self-managed event) 
was assumed to imply the use of 5.3 glucometer strips and a visit to a general practi-
tioner for 25% of patients (Orozco-Beltrán et al., 2014). The disutility value associated 
to weight gain was -0.0100 per BMI unit (Lee et al., 2005). The disutility associated to 
daytime and nocturnal non-severe hypoglycemia was -0.0041 and -0.0067 per event, 
respectively (Evans et al., 2013). Results: The yearly gain in quality-adjusted life 
years (QALY) associated to insulin detemir versus NPH was 0.015. The estimated 
incremental cost of treating patients with insulin detemir versus NPH was € 244.03. 
The incremental cost-effectiveness ratio (ICER) of insulin detemir versus NPH in 
insulin-naïve T2DM patients was estimated to be € 16,381.18/QALY in Spain. This 
value is lower than those published for other European countries (€ 21,768-28,349/
QALY) and is beneath the ICER threshold commonly accepted for Spain (€ 30,000/
QALY). ConClusions: Insulin detemir is a cost-effective alternative to NPH insulin in 
the first and subsequent years of treatment of insulin-naïve T2DM patients in Spain.
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objeCtives: To estimate the short-term cost-effectiveness of insulin detemir 
compared with Neutral Protamine Hagedorn (NPH) insulin when initiating insulin 
treatment in patients with Type 1 Diabetes Mellitus (T1DM) in Spain. Methods: A 
short-term (1 year) cost-effectiveness model was adapted to the Spanish public health 
care system. Based on the Update of CADTH Technology Report No. 92 (2008) that 
showed similar efficacy in glycemic control for both insulin types, the rate of hypo-
glycemia with detemir vs. NPH (RR= 0.84; IC95% 0.74-0.97) was the considered clinical 
outcome. Costs, expressed in Euros 2014, were estimated from the perspective of the 
Spanish national health system and derived from national health care cost databases 
and publications. Only insulin treatment and management costs associated with 
non-severe hypoglycemic episodes were included in the analysis. Non-severe hypo-
glycemia, defined as a self-managed event, was assumed to imply the use of extra 5.3 
glucometer strips during the following week and a visit to a general practitioner for 
25% of patients (Orozco-Beltrán et al., 2014). The disutility associated to daytime and 
nocturnal non-severe hypoglycemia was -0.0041 and -0.0067 per event, respectively 
(Evans et al., 2013). Results: The gain in quality-adjusted life years (QALY) associated 
to determir versus NPH was 0.108. The estimated incremental cost of determir versus 
NPH was € 247.40. The incremental cost-effectiveness ratio (ICER) of detemir vs. NPH 
in patients with T1DM was estimated to be € 2,286.67/QALY in Spain. This value is 
significantly lower than those reported for other European countries (€ 10,938-13,310/
QALY) and are much lower than the ICER threshold commonly accepted for Spain 
(€ 30,000/QALY). ConClusions: Detemir is a cost-effective alternative to NPH insulin 
in the first year of treatment of insulin-naive T1DM patients in Spain.
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objeCtives: Since more than 45 years, a preventive program for the detection of 
congenital metabolic and endocrine diseases is carried out successfully in Austria. The 
goal is to investigate every new-born a few days after birth to initiate a quality assured 
therapy as quickly as possible. Since 1966, this program is carried out by the Federal 
Ministry of Health at the University Clinic for Child and Adolescent Medicine, Medical 
University of Vienna. The aim of this study was to determine cost-effectiveness of 
the new-born screening. Methods: We developed a decision-analytic model, which 
include specific Markov processes for the core disorders: Cystic Fibrosis (CF), phe-
nylketonuria (PKU), medium-chain acyl-CoA (MCAD), congenital hypothyroidism (CH), 
galactosemia (GAL) and Maple syrup urine disease (MSUD). Costs and health benefits 
were estimated for a cohort of new-borns in Austria in 1 year. The analysis focused 
on lifetime consequences. This encompassed direct costs (including screening costs 
and cost of illness), quality-adjusted-life-years (QALYs) and reduced expectation of 
life. Costs were presented per child and for the Austrian birth cohort. Costs from 
published sources were used (2014 Euro) from the health care systems perspective. 
QALYs, life-years (LYs) and costs were projected over a life-time horizon and dis-
counted at 3% p. a. Results: We found ten-times higher lifetime costs per child 
without screening compared to screening. The incremental costs of screening ranged 
from 12.308 € (MCAD) to 291.332 € (PKU). Screening saved 181 € and 0.09 QALYs per 
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objeCtives: Two SGLT-2 inhibitors, CANA and DAPA, are recommended in the UK 
for combination therapy in T2DM. Through an insulin-independent mechanism of 
action, SGLT-2 inhibitors improve glucose levels, blood pressure, and weight with a 
low inherent risk of hypoglycaemia. The cost-effectiveness of using CANA or DAPA 
in combination with MET was evaluated in patients inadequately controlled with 
MET monotherapy, from the perspective of the UK NHS. Methods: The ECHO-
T2DM model was used to estimate 40-year outcomes and costs associated with 
using CANA (100mg or 300mg) versus DAPA 10mg in dual therapy. HbA1c efficacy 
estimates were obtained from a Network Meta-Analysis (NMA). Analyses of pooled 
data from trials investigating CANA dual therapy (with MET) were used for param-
eters unavailable in the NMA (i. e., SBP, LDL, HDL and AEs). A broad set of sensitiv-
ity analyses were performed. Results: Both doses of CANA were associated with 
more QALYs (0.01,0. 03 for 100mg and 300mg, respectively) and higher costs (£101, 
£594, respectively). The associated incremental cost-effectiveness ratios (ICERs) were 
£7,423 and £17,734, respectively; both below the willingness-to-pay for QALY thresh-
old in the UK. The key driver of the result for CANA 300mg was the greater HbA1c 
efficacy versus DAPA 10mg, and for CANA 100mg, a lower need for insulin rescue 
since CANA (but not DAPA) can be used in persons with moderate renal impair-
ment. The ICERs were robust under all scenarios tested. Only use of UK-specific and 
not clinical trial patient characteristics substantively impacted the results; none 
reversed the interpretation of CANA as cost-effective versus DAPA. ConClusions: 
SGLT-2 inhibitors reduce HbA1C, body weight, and blood pressure, and thus the risk 
of micro- and macrovascular complications. Economic simulations suggest that 
both doses of CANA are cost-effective versus DAPA in dual therapy treatment of 
T2DM (with MET) in the UK.
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objeCtives: To project the long-term costs and outcomes of sensor-augmented 
pump (SAP) with low glucose suspend (LGS) versus insulin pump (CSII) alone for the 
treatment of hypo-prone Type 1 diabetes in Hungary. Methods: The CORE Diabetes 
Model is a peer-reviewed, validated model, which employs standard Markov/Monte 
Carlo simulation techniques to describe the long-term incidence and progression 
of diabetes-related complications. It was used to simulate disease progression in a 
cohort of patients with baseline characteristics (mean age 18.6 years, duration of 
diabetes 12 years, mean HbA1c 7.5%) and clinical outcomes (severe hypoglycaemic 
event rates; Quality of Life; HbA1c) taken from a recent randomised controlled 
trial (Ly et al, 2013). Local treatment and complication cost data was used. The 
main scenario considered in this cost-effectiveness analysis was the comparison 
of sensor-augmented insulin pump (SAP) with low glucose suspend (LGS) versus 
pump alone (CSII). The target population was hypo-prone type I diabetes patients 
with the analysis based on a deterministic microsimulation of 1,000 patients, using 
a 1 to 5 year time horizon. Direct costs were calculated from a third-party payer 
perspective. Discount rates of 3.7% per annum were applied to both costs and 
clinical outcomes. Results: The Incremental-Cost-Effectiveness-Ratio (ICER) for 
SAP+LGS vs CSII was HUF 6,196,086 (€ 20,298) per Quality-Adjusted-Life-Year gained 
over a 1 year time horizon. Results were similar using a 5 year time horizon (HUF 
6,125,823 [€ 20,068] per QALY gained). Extensive sensitivity analyses showed the 
robustness of the results. ConClusions: Using a payer’s perspective, our analysis 
showed that SAP (w LGS) is cost-effective over a short term (1-5 year) time horizon 
in hypo prone patients with Type 1 Diabetes in Hungary (using a WTP threshold of 
3x Hungary GDP).
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objeCtives: New classes of anti-diabetes drugs may delay the onset of Insulin 
treatment. This study investigates the cost-effectiveness of a treatment path-
way starting with dapagliflozin (Forxiga®), followed by exenatide once weekly 
(Bydureon®) - both as add-on to metformin - and insulin treatment, compared 
with a treatment pathway recommended in clinical guidelines that commences 
with SU add-on to metformin, followed by the addition of insulin regimens in 
patients inadequately controlled with metformin alone. Methods: The validated 
CARDIFF model was used for the analyses. Clinical inputs for dapagliflozin ver-
sus SU, both as add-on to metformin, and exenatide once weekly were derived 
from relevant head-to-head clinical trials and long-term follow up studies. Based 
on these and the United Kingdom Prospective Diabetes Study (UKPDS) equations, 
the model predicts disease progression and number of micro- and macro-vascular 
complications, along with diabetes-specific and all-cause mortality. The perspec-
tive of the National Health Service in UK was adopted over a lifetime horizon. Local 
unit costs and utility data were assigned to the appropriate model parameters 
to calculate total Quality-Adjusted-Life-Years (QALYs) and costs. Deterministic 
and probabilistic sensitivity analyses (PSA) were conducted. Results: Long-term 
evidence showed that the durability of the treatment effects of dapagliflozin and 
exenatide can delay the onset of insulin treatment by 5-6 years. Compared to the 
traditional clinical practice, treatment with dapagliflozin+metformin followed by 
exenatide+metformin, was associated with an incremental benefit of 0.343 QALYs 
(95%CI: 0.239; 0.450) at an additional cost of £2,827 (95%CI: £2,352; £3,267), result-
ing in an incremental cost-effectiveness ratio of £8,233 per QALY gained. The PSA 
and results in higher QALYs in comparison with sitagliptin 100 mg in dual therapy as 
add-on to metformin and in triple therapy as add-on to MET plus SU. In dual therapy 
as add-on to MET, canagliflozin (100 mg and 300 mg weighted average 65: 35) has 
an average cost saving of 24 € and an average QALY gain of 0.036. In triple therapy 
as add-on to MET+SU, canagliflozin (100 mg and 300 mg weighted average 65: 35) 
has an average cost saving of 171 € and an average QALY gain of 0.033. Probabilistic 
analysis suggests a likelihood of 59% of canagliflozin being cost-effective compared to 
sitagliptin in dual therapy and 59% in triple therapy at a willingness-to-pay of 30,000 
€ per gained QALY. Sensitivity analyses showed that canagliflozin is cost-effective 
also from a payer perspective and even when the time horizon, which is 30 years in 
the base case, is reduced to 10 years. ConClusions: Canagliflozin 100 mg and 300 
mg will be a cost-effective alternative to sitagliptin in both dual and triple therapies, 
as add-on to MET or as add-on to MET+SU, respectively.
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objeCtives: Canagliflozin is a sodium glucose co-transporter 2 (SGLT2) inhibitor 
developed for the treatment of adult patients with type 2 diabetes mellitus (T2DM). 
To evaluate the cost-effectiveness of canagliflozin in dual therapy as add-on to 
metformin (MET) compared to sitagliptin, and in triple therapy (add on to MET 
and sulphonylurea (SU)) compared to sitagliptin, liraglutide and a mixed strategy 
with both drugs. Methods: The IMS CORE Diabetes Model was used to evaluate 
the cost-effectiveness of canagliflozin versus the aforementioned comparators 
using French-specific data, where available. Results: In dual therapy, as add-
on to metformin versus sitagliptin, canagliflozin (100 mg and 300 mg weighted 
average 50: 50) resulted in an incremental cost of 392 € and an average QALY gain 
of 0.013, which leads to an ICER of 30,154 € . In triple therapy canagliflozin (100 
mg and 300 mg weighted average 50: 50) dominates sitagliptin with average cost 
savings of 286 € and an average QALY gain of 0.050. Canagliflozin was estimated 
to be cost-saving (1,280 € ) compared to liraglutide (distribution liraglutide 1.2 
mg / 1.8 mg= 0.71/0.29 based on French market research data) with incremen-
tal QALYs of -0.015. Canagliflozin (100 mg and 300 mg weighted average 50: 50) 
dominates a mixed strategy with liraglutide (12.5%) and sitagliptin (87.5%) average 
cost saving of 410 € and average QALY gain of 0.041. Sensitivity analyses showed 
that HbA1cand SBP treatment effects were key drivers of the cost effectiveness 
results. ConClusions: Canagliflozin 100 mg and 300 mg will be a cost-effective 
alternative to sitagliptin in dual therapy as add-on to metformin. In triple therapy 
as add-on to metformin and SU, canagliflozin dominates in comparison with a 
mix of patients treated with sitagliptin or liraglutide. Canagliflozin 100 mg or 
300 mg is expected to be considered good value for money for the treatment of 
T2DM in France.
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objeCtives: In patients with type 2 diabetes (T2D) receiving basal insulin therapy, 
the addition of bolus insulin is a common therapeutic strategy once glycated hemo-
globin (HbA1c) becomes uncontrolled. However, this strategy is associated with 
weight gain and increased risk of hypoglycemia. The objective was to assess the 
cost-effectiveness of exenatide twice daily (BID) (‘ExBID’) versus insulin lispro three 
times daily (TID) (‘LisTID’) as add-on therapy to titrated insulin glargine in patients 
with T2D, from the Swedish health care perspective. Methods: This analysis uti-
lized the Cardiff Model, a previously published T2D disease model. Treatment effects 
were taken from the 4B Study, where ExBID and LisTID resulted in similar glycemic 
control with less hypoglycemia with ExBID. Furthermore, ExBID was associated 
with a weight loss of 2.6kg and LisTID with a weight gain of 1.9kg. An assumption 
made in this analysis is that once the HbA1c level returned to its baseline value, 
patients escalated to intensified basal-bolus therapy based on published treatment 
effects. Quality-adjusted life years (QALYs) were calculated, with health-state utili-
ties applied to weight changes, hypoglycemia, and T2D-related complications. Costs 
(Swedish kronor, SEK) included medication and T2D-related complications. The 
model was run over a 40-year time horizon. Costs and QALYs were discounted at 
3% annually. Results: Cost/patient with ExBID and LisTID was SEK 381,177 and 
SEK 364,381, respectively. ExBID was associated with a QALY gain of 0.64 per patient 
versus LisTID (11.51 and 10.86 QALYs, respectively). This result was driven by the 
difference in weight between ExBID and LisTID. The cost/QALY gained with ExBID 
versus LisTID was SEK 26,292. ConClusions: With a cost/QALY gained of SEK 
26,292 (3,039 Euros, 2,582 British pounds, 4,033 US dollars), evaluated against com-
monly used cost-effectiveness threshold values, ExBID represents a cost-effective 
treatment alternative to LisTID as add-on therapy to titrated insulin glargine in 
patients with T2D in Sweden.
PDB71
The cosT-effecTIveness of canagLIfLozIn (cana) versus DaPagLIfLozIn 
(DaPa) In PaTIenTs WITh TyPe 2 DIaBeTes meLLITus (T2Dm) WITh 
InaDequaTe conTroL on meTformIn (meT) monoTheraPy In The unITeD 
kIngDom
Schroeder M.1, Johansen P.2, Thompson G.1, Willis M.3, Neslusan C.4
1Janssen-Cilag UK, High Wycombe, UK, 2The Swedish Institute for Health Economics (IHE), Lund, 
Sweden, 3The Swedish Institute for Health Economics, Lund, Sweden, 4Janssen Global Services, 
LLC, Raritan, NJ, USA
